Login to Your Account

Race to Market in HAE

Lev's C1 Inhibitor Approvable in HAE, but Questions Remain

By Jennifer Boggs

Friday, February 1, 2008
Shares of Lev Pharmaceuticals Inc. tumbled 33 percent after the FDA requested additional information - though likely no new trials - prior to an approval of Cinryze, the company's C1 inhibitor in hereditary angioedema. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription